St. Louis Arch Angels

SentiAR is a digital health software company developing a 3D augmented reality holographic platform that provides real-time visualization of a patient’s anatomy and catheter location during interventional procedures. Spun out from Washington University, it uses real-time mapping data and imaging from CT/MRI to render holographic views over the patient in the catheterization laboratory, with clinician-controlled visualization. The platform aims to improve precision and safety in procedures addressing cardiac arrhythmias. The company focuses on delivering an immersive visualization solution for interventional cardiology and related specialties.

CoverCress Inc. specializes in developing and commercializing field pennycress as a sustainable oilseed crop for industrial oils and livestock feed. Founded in 2013, the company is headquartered in Saint Louis, Missouri.

FinLocker, LLC is a financial technology company based in St. Louis, Missouri, founded in 2014. It specializes in developing a consumer-enabled financial data platform that enhances the loan process for mortgages and various financial products. FinLocker provides a personal financial assistant tool that captures essential borrower data with consumer consent, utilizing intelligent analytics to offer tailored loan product recommendations based on individual financial profiles. Its solutions aim to streamline lending processes by improving data collection, verification, and analytics, thereby reducing costs, time, and risks for lenders. Additionally, FinLocker enhances the borrower experience by enabling consumers to manage their finances more effectively, apply for loans with reduced documentation hassles, and control data sharing.

Ryvit develops integration software tailored for the construction industry. Its platform facilitates seamless data flow between various premise-based and cloud software applications, including enterprise resource products, CRM, e-commerce platforms, social apps, and industry-specific systems. Headquartered in Saint Louis, Missouri, Ryvit empowers businesses to automate workflows and optimize application usage without straining development resources.

Founded in 2016, CheckTheQ offers a subscription service for tracking and communicating wait times in real-time. Serving airports, stadiums, and venues, the company aims to optimize operations and enhance customer experience.

Lean Media, Inc. is a digital advertising company specializing in cookieless audience targeting services tailored for agribusiness and rural community advertisers. Founded in 2014 and based in Chesterfield, Missouri, the company employs advanced geo-targeting technology to connect with consumers at an individual level by analyzing IP addresses in conjunction with consumer databases. Lean Media's platform enables advertisers to customize campaigns based on specific workplaces, demographics, psychographics, and behavioral insights, allowing for more effective engagement and reduced advertising waste. The company focuses on delivering confidence to advertisers by enhancing their ability to reach target consumers through programmatic online display advertising.

Transactly is a real estate technology platform founded in 2018 and based in St. Charles, Missouri. It focuses on organizing and coordinating the closing process of real estate transactions across the United States. As the first tech-enabled transaction coordinator service, Transactly provides customers with a dedicated coordinator backed by a comprehensive support team. The platform aims to streamline real estate transactions for home buyers and sellers, enhancing transparency and efficiency. By managing the various tasks involved in the transaction process, Transactly enables real estate professionals, such as brokers and agents, to improve their service offerings and increase their revenue potential.

SwipeSum operates a payment processing management platform that helps businesses optimize merchant services and reduce costs by auditing merchant statements with proprietary software and advising on payment strategies. Its technology simplifies payment infrastructure, supports integrated payments and partnerships with software vendors and financial institutions, and aims to convert payments into a revenue-driving function. The company also offers an AI-powered statement analysis tool used to create quick cost comparisons and proposals for clients and partner organizations.

Aptimmune is a biotechnology company headquartered in St. Louis, Missouri, established in 2010. It specializes in the development of mucosal vaccines aimed at preventing viral diseases in swine, specifically targeting the Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and influenza A virus. By employing innovative technologies, including a proprietary pig alveolar macrophage cell line known as ZMAC, Aptimmune creates effective nasal delivery vaccines that provide lasting immune responses and enhance disease protection for animal breeders.

CoverCress Inc. specializes in developing and commercializing field pennycress as a sustainable oilseed crop for industrial oils and livestock feed. Founded in 2013, the company is headquartered in Saint Louis, Missouri.

Kogent Surgical, LLC specializes in the design, manufacture, and marketing of surgical and neurosurgical instruments. Founded in 2011 and based in Chesterfield, Missouri, the company offers a diverse range of products, including forceps, curettes, suture pushers, knives, and lighted suction tubes. Kogent Surgical is recognized as an industry leader in neurosurgical instruments, with a focus on providing high-quality products that enhance surgical precision and efficiency. The instruments are made from lightweight, non-magnetic titanium, suitable for both disposable and reusable applications in electrosurgery and microsurgery. Additionally, Kogent Surgical provides repair and restoration services for surgical instruments, ensuring their longevity and functionality. The company's products are available online and distributed globally, reflecting its commitment to superior service and cost-effective solutions for medical professionals.

Euclises Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing, and commercializing innovative medicines for inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company aims to create novel pain and cancer treatments that demonstrate superior safety profiles compared to existing medications. Euclises Pharmaceuticals leverages groundbreaking inventions from Dr. John Talley, a renowned medicinal chemist known for his development of several approved drugs, including Celebrex. The company's research is centered on compounds that promise enhanced efficacy and safety, positioning Euclises as a significant player in the pharmaceutical industry. It operates out of the BioGenerator Accelerator Labs, fostering a collaborative environment for its innovative pursuits.

FocalCast LLC, founded in 2013 and located in St. Louis, Missouri, is a technology company that specializes in developing an interactive web-based platform for market research. The platform allows users to simultaneously share and annotate documents and whiteboards in real time from any device, enhancing collaboration for global brands and marketing agencies. FocalCast's offerings include tools for stimuli and content presentation, live annotations, project management, and polling and data services. Users can easily connect with research participants without needing to download additional software, facilitating seamless presentations directly from smartphones or tablets to display devices like projectors or smart TVs.

Radialogica LLC, established in 2011 and headquartered in St. Louis, Missouri, is a healthcare information technology company specializing in radiation oncology software solutions. The company's flagship product, fullAccess, is an integrated platform enabling clinicians across various care settings to access, analyze, and share radiotherapy treatment plans, diagnostic images, and other patient data. This platform also facilitates content delivery, course instruction, and student assessment for academic programs associated with radiation oncology. Additionally, Radialogica offers OncoInformatix, a web-based tool for radiotherapy treatment data acquisition, aggregation, analysis, and reporting. The company serves healthcare providers and payers in the United States.

Euclises Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing, and commercializing innovative medicines for inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company aims to create novel pain and cancer treatments that demonstrate superior safety profiles compared to existing medications. Euclises Pharmaceuticals leverages groundbreaking inventions from Dr. John Talley, a renowned medicinal chemist known for his development of several approved drugs, including Celebrex. The company's research is centered on compounds that promise enhanced efficacy and safety, positioning Euclises as a significant player in the pharmaceutical industry. It operates out of the BioGenerator Accelerator Labs, fostering a collaborative environment for its innovative pursuits.

Confluence Life Sciences, Inc. is a drug discovery company based in Saint Louis, Missouri, specializing in the design and development of mechanistically novel kinase inhibitors for human and animal health care. Founded in 2010, the company utilizes its KINect technology platform to identify and develop new drugs targeting key enzymes involved in cancer growth, survival, and metastasis, as well as in chronic inflammatory diseases. Confluence Life Sciences distinguishes itself by focusing on novel binding sites and previously undrugged kinases, addressing challenges that other programs have overlooked. The company is supported by a team of experts with extensive pharmaceutical experience in kinase inhibitor discovery and development, enabling it to pursue innovative strategies and targets. Confluence Life Sciences aims to establish scientific and business collaborations to enhance its program pipeline, which follows a cycle of discovery, development, and partnership to meet unmet medical needs.

CoverCress Inc. specializes in developing and commercializing field pennycress as a sustainable oilseed crop for industrial oils and livestock feed. Founded in 2013, the company is headquartered in Saint Louis, Missouri.

Euclises Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing, and commercializing innovative medicines for inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company aims to create novel pain and cancer treatments that demonstrate superior safety profiles compared to existing medications. Euclises Pharmaceuticals leverages groundbreaking inventions from Dr. John Talley, a renowned medicinal chemist known for his development of several approved drugs, including Celebrex. The company's research is centered on compounds that promise enhanced efficacy and safety, positioning Euclises as a significant player in the pharmaceutical industry. It operates out of the BioGenerator Accelerator Labs, fostering a collaborative environment for its innovative pursuits.

GeneriCo, LLC is a pharmaceutical company that specializes in the development and marketing of generic medications. Founded in 2013 and headquartered in Saint Louis, Missouri, with additional offices in Bengaluru, India; Italy; and South Korea, GeneriCo focuses on foundational medicines across various therapeutic areas, including cardiovascular health, pain management, central nervous system disorders, oncology, and aging-related conditions. The company distinguishes itself by targeting niche generic pharmaceuticals that have been overlooked by larger competitors, particularly those that involve complex formulations and innovative drug delivery technologies. This strategic focus allows GeneriCo to address specific market needs that are often neglected by mid-sized and large generic companies. GeneriCo serves a global customer base, providing essential medications that contribute to improved health outcomes.

RnAgri is a biotechnology company based in St Louis, Missouri, founded in 2011. The company specializes in developing innovative technology for producing ribonucleic acid (RNA). RnAgri's technology tackles challenges associated with mass-producing exogenous RNAi-based products through large-scale fermentation processes. This enables farmers to enhance and safeguard their crops and cattle by providing cost-efficient RNA production solutions.

RnAgri is a biotechnology company based in St Louis, Missouri, founded in 2011. The company specializes in developing innovative technology for producing ribonucleic acid (RNA). RnAgri's technology tackles challenges associated with mass-producing exogenous RNAi-based products through large-scale fermentation processes. This enables farmers to enhance and safeguard their crops and cattle by providing cost-efficient RNA production solutions.

ImmunoPhotonics, Inc. is a biotechnology company focused on developing innovative immunotherapy-based treatments for cancer, specifically targeting metastatic solid tumors. Founded in 2008 and headquartered in Columbia, Missouri, the company has created a proprietary drug product that functions as a minimally invasive autologous cancer vaccine. This treatment involves the intratumoral injection of a carbohydrate polymer following tumor ablation, which harnesses the immune system's response to tumor-associated neoantigens released during the process. By doing so, ImmunoPhotonics aims to generate a systemic anti-tumor immune response, facilitating the treatment of late-stage metastatic cancers. The company has established a strategic partnership with Veterinary Cancer Therapeutics, LLC, enhancing its potential for clinical application.

Elira is a weight-management technology company based in St. Louis, Missouri, founded in 2015. It develops a drug-free wearable device that non-invasively modulates the central nervous system to suppress appetite, enabling overweight adults to better control their food intake. The device is worn as a patch and aims to support health and lifestyle goals by reducing cravings and eating behavior without pharmaceuticals. The company focuses on neurostimulation as an alternative to traditional therapies for appetite regulation.

Epharmix, Inc. is a digital healthcare company that specializes in developing clinically validated, condition-specific communication tools designed for the healthcare industry. Founded in 2015 and based in St. Louis, Missouri, the company creates digital interventions tailored to various patient populations, aimed at enhancing patient-physician engagement. Epharmix's products facilitate the automatic collection of clinical data over time, which allows for algorithmic alerts to healthcare providers, thereby supporting chronic care management for patients. By focusing on underserved patient groups, Epharmix enables care teams to improve healthcare delivery while reducing workload through proven interventions that enhance both engagement and health outcomes.

Aisle411 Inc., founded in 2008 and based in St. Louis, Missouri, offers a mobile in-store location services platform for retailers. The company's platform enables shoppers to easily navigate retail stores by mapping products, offers, and lists by aisle location, providing unique information based on the shopper’s in-store location. This enhances the shopping experience by allowing retailers to reach shoppers at the shelf with contextually relevant information. Aisle411 collects, organizes, and monetizes retailers’ product inventory, location data, and enterprise software space planning systems and store maps. The company has partnered with leading indoor positioning technology providers to offer shopper positioning services that drive merchandising insights and engaging shopping experiences, ultimately increasing customer satisfaction and retailer engagement.

Euclises Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing, and commercializing innovative medicines for inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company aims to create novel pain and cancer treatments that demonstrate superior safety profiles compared to existing medications. Euclises Pharmaceuticals leverages groundbreaking inventions from Dr. John Talley, a renowned medicinal chemist known for his development of several approved drugs, including Celebrex. The company's research is centered on compounds that promise enhanced efficacy and safety, positioning Euclises as a significant player in the pharmaceutical industry. It operates out of the BioGenerator Accelerator Labs, fostering a collaborative environment for its innovative pursuits.

Adarza BioSystems is an early-stage medical diagnostics company based in St. Louis, Missouri, that specializes in developing a rapid and label-free biological assay platform for clinical and point-of-care samples. Founded in 2008, the company utilizes its innovative arrayed imaging reflectometry technology to enable the simultaneous detection of hundreds of analytes from a single drop of fluid. This platform allows healthcare professionals to conduct sophisticated tests in a matter of minutes, ensuring high sensitivity and specificity in the detection of multiplexed proteins. Adarza BioSystems aims to enhance diagnostic capabilities, improving patient outcomes through quicker and more accurate testing.

Elemental Enzymes Inc. is a manufacturer based in Columbia, Missouri, specializing in the production of enzymes designed to function in harsh environments, both in outdoor settings and industrial applications. The company offers a diverse range of enzyme products, including those for agricultural use, environmental remediation, and fuel production. Their offerings include enzymes that degrade cellulose, starches, and sugars, stable alternatives to caustic chemicals for digesting fracking gels, and solutions for converting CO2 into carbonate for capture or sale. Additionally, Elemental Enzymes develops customized enzyme solutions to address common environmental contaminants and creates enzymes for various non-environmental applications. The company was originally established as Spogen Biotech, Inc. in 2011 before rebranding to its current name.

Akermin, Inc. is a biocatalyst development company based in St. Louis, Missouri, founded in 2003. The company specializes in innovative solutions for the removal of carbon dioxide (CO2) from industrial gas streams, utilizing biocatalysis and nanotechnology. Akermin has developed proprietary delivery systems that enable the integration of enzymes into traditional chemical absorption processes for effective CO2 removal. In addition to its primary focus on carbon capture, Akermin is also exploring applications of its stabilized enzyme technology in various sectors, including food processing, biofuels, chemicals, and pharmaceuticals. The company aims to commercialize its technology, which originated from research at Saint Louis University, and has demonstrated its capabilities in developing sustainable solutions for a range of industries.

Founded in 2011 and headquartered in St. Louis, Missouri, Tunespeak operates a musician-to-fan loyalty platform. Its platform enables users to earn points by engaging with music content such as listening to songs, watching videos, browsing photos, and sharing with friends.

BenchmarkONE is a St. Louis, Missouri-based company that specializes in developing sales and marketing automation software for small and mid-sized businesses. Founded in 2010 and previously known as Hatchbuck, Inc., BenchmarkONE provides an all-in-one customer relationship management (CRM) platform that includes features for sales automation, real-time activity monitoring, and email marketing. Its user-friendly interface allows businesses to create and manage campaigns, track leads, and analyze performance metrics effectively. The software is designed to streamline the sales process, enhance customer engagement, and facilitate the growth of relationships into sales. As of June 2020, BenchmarkONE operates as a subsidiary of Benchmark Internet Group, LLC.

Founded in 2007, Neurolutions develops non-invasive brain-computer interface devices aimed at restoring functionality to individuals disabled by neurological injuries. Their technology uses electroencephalography (EEG) electrodes to interpret intended muscle movements, facilitating rehabilitation and maintaining range of motion.

Kypha Inc. is a life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Through its innovative platform, Kypha provides rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. The company's approach facilitates testing across diverse settings, from home health care to clinical laboratories, ultimately aiming to improve patient outcomes by optimizing treatment strategies based on real-time immune insights. Since its incorporation in 2009, Kypha has attracted significant funding and built a strong network of scientific and clinical expertise to support its mission.

Euclises Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing, and commercializing innovative medicines for inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company aims to create novel pain and cancer treatments that demonstrate superior safety profiles compared to existing medications. Euclises Pharmaceuticals leverages groundbreaking inventions from Dr. John Talley, a renowned medicinal chemist known for his development of several approved drugs, including Celebrex. The company's research is centered on compounds that promise enhanced efficacy and safety, positioning Euclises as a significant player in the pharmaceutical industry. It operates out of the BioGenerator Accelerator Labs, fostering a collaborative environment for its innovative pursuits.

Founded in 2013, Bonfyre operates an employee engagement platform that facilitates communication, recognition, feedback, events, and more. Its mobile-first, real-time tools help enterprises build camaraderie, align culture, and drive HR business intelligence.

Traxxsson is a biotechnology company that develops diagnostics for cancer using protein biomarkers. It uses a proprietary panel of biomarkers to identify at-risk patients who have questionable radiology images. It has three tests: PRO CancSure to identify prostate cancer patients in need of aggressive treatment, BRE CancSure to confirm the presence of breast cancer in women with positive mammograms, and LNG CancSure to confirm the presence of lung cancer in patients with positive low-density CAT scan results. The company was founded in 2009 and is based in St. Louis, Missouri.

Euphrates Vascular is a medical technology company based in St. Louis, Missouri, that focuses on innovative solutions for the treatment of stroke, heart disease, and other conditions. The company has developed a proprietary magnetically-enhanced diffusion (MED) system that utilizes magnet-based technology to dissolve blood clots more rapidly than existing treatment options. This system aims to improve the efficacy of FDA-approved clot-busting medications, potentially reducing mortality rates associated with stroke and cardiovascular diseases. In addition to the MED system, Euphrates Vascular offers MED MicroBeads, which are designed to deliver therapeutic agents directly to clots during thrombolysis therapy, and a touch screen-operated MED Workstation. Founded by physicists with extensive experience in medical technology, the company continues to advance its pioneering approaches in the healthcare sector, attracting interest from investors and media alike.

Katalyst Surgical, LLC is a manufacturer of ophthalmic surgical instruments, specializing in providing innovative tools designed to enhance surgical techniques, particularly for membrane peeling. Founded in 2010 and based in Chesterfield, Missouri, the company offers a comprehensive range of products, including cannulas, forceps, hooks and manipulators, LASIK instruments, needle holders, phaco choppers, scissors, speculums, and other related items. Katalyst Surgical is committed to enabling medical practitioners to perform surgical procedures more effectively through its high-quality, specialized instruments.

Akermin, Inc. is a biocatalyst development company based in St. Louis, Missouri, founded in 2003. The company specializes in innovative solutions for the removal of carbon dioxide (CO2) from industrial gas streams, utilizing biocatalysis and nanotechnology. Akermin has developed proprietary delivery systems that enable the integration of enzymes into traditional chemical absorption processes for effective CO2 removal. In addition to its primary focus on carbon capture, Akermin is also exploring applications of its stabilized enzyme technology in various sectors, including food processing, biofuels, chemicals, and pharmaceuticals. The company aims to commercialize its technology, which originated from research at Saint Louis University, and has demonstrated its capabilities in developing sustainable solutions for a range of industries.

Appistry Inc. is a bioinformatics company based in St. Louis, Missouri, that specializes in developing tools and cloud services for healthcare institutions to enhance genomically informed medicine. Founded in 2001 and originally known as Tsunami Research, Appistry provides a suite of solutions that streamline the analysis of next-generation sequencing (NGS) data, making it accessible and actionable for clinical laboratories, research institutions, and hospitals. Its flagship offerings include Appistry CloudDx, which supports patient-centered translational research and facilitates the integration of genome-scale tests into routine clinical practice. Additionally, the company offers tools for analyzing whole genomes, exomes, and tumor-normal pair data, as well as platforms like GenomePilot and the Cancer Genome Analysis Suite, which organize and execute complex NGS analyses. By leveraging cloud architecture, Appistry addresses the challenges of large-scale data storage and processing, enabling rapid transformation of raw genomic data into actionable insights that inform clinical decisions and research initiatives.